Fostamatinib治疗MTX应答不佳的亚洲类风湿关节炎患者的II期研究
两项II期研究评估了fostamatinib在甲氨蝶呤(MTX)治疗下仍活动的大亚洲类风湿关节炎(RA)患者中的疗效与长期安全性。OSKIRA-Asia-1为12周双盲安慰剂对照研究,OSKIRA-Asia-1X为长期扩展研究。结果显示fostamatinib在部分剂量组达到ACR20/50/70及低疾病活动度的统计学显著改善,安全性与既往研究一致。
要点
- Fostamatinib在部分剂量组对MTX应答不佳的亚洲RA患者显示ACR20/50/70的统计学显著改善。
- 常见不良事件包括高血压、腹泻和中性粒细胞减少。
- 长期扩展研究安全性与既往研究一致。
核心结论
- Fostamatinib在RA体征和症状方面取得了统计学和临床显著的改善。
- Fostamatinib(联合MTX)的安全性和耐受性与既往研究一致。
研究设计与样本
- OSKIRA-Asia-1为12周、多中心、双盲、安慰剂对照、平行组研究,患者随机接受四种fostamatinib剂量之一(A-D组,n=31、33、33、33)或安慰剂(E组,n=33)。
- OSKIRA-Asia-1X为长期扩展研究,纳入完成OSKIRA-Asia-1的患者,接受fostamatinib 100 mg每日一次。
主要发现
- 在第12周,A组(100 mg每日两次)和B组(100 mg每日两次,后改为150 mg每日一次)的ACR20应答较安慰剂有数值上的改善。
- A组和B组在第8周ACR20和ACR50、第12周ACR70以及基于C反应蛋白的28关节计数DAS≤3.2的低疾病活动度方面达到统计学显著改善。
- A组身体功能改善在数值上更高。
- OSKIRA-Asia-1中最常见的不良事件为高血压、腹泻和中性粒细胞减少;OSKIRA-Asia-1X中最常见的不良事件为鼻咽炎、高血压、RA和中性粒细胞减少。
关键数值与推荐
- 低疾病活动度定义为基于C反应蛋白的28关节计数DAS≤3.2。
- 疗效通过ACR应答标准和基于28关节计数的DAS评估。
- 身体功能状态通过HAQ残疾指数评估。
临床怎么用
- 对于MTX应答不佳的亚洲RA患者,fostamatinib联合MTX可能改善疾病活动度和身体功能。
- 使用fostamatinib时应监测高血压、腹泻和中性粒细胞减少等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The primary objectives of two phase II studies of fostamatinib were to evaluate efficacy (OSKIRA-Asia-1: NCT01569074) and long-term safety/tolerability (OSKIRA-Asia-1X: NCT01640054) in patients from Asia with active RA despite MTX treatment. METHODS: OSKIRA-Asia-1 was a 12-week, multicentre, double-blind, placebo-controlled, parallel-group study. Patients were randomized to receive one of four fostamatinib doses (groups A-D; n = 31, 33, 33, 33) or placebo (group E; n = 33). OSKIRA-Asia-1X was a long-term extension study (100 mg fostamatinib qd) of patients who completed OSKIRA-Asia-1. RA signs and symptoms were measured by ACR response criteria and DAS based on a 28-joint count. Physical function status was assessed with the HAQ-Disability Index. Safety findings were monitored. RESULTS: In OSKIRA-Asia-1, fostamatinib revealed numerical improvements in ACR 20% response (ACR20) at week 12 in group A (100 mg bid) and group B (100 mg bid, then 150 mg qd) vs placebo. Statistically significant improvements in ACR20 and ACR50 at week 8 and in ACR70 at week 12, and statistically significant achievement in low disease activity (defined as DAS based on a 28-joint count ≤3.2 based on C-reactive protein) occurred in groups A and B. Improvement in physical function was numerically higher in group A. The most common adverse events were hypertension, diarrhoea and neutropenia. In OSKIRA-Asia-1X, the most common adverse events were nasopharyngitis, hypertension, RA and neutropenia. CONCLUSION: Fostamatinib achieved both statistically and clinically significant improvements in RA signs and symptoms. The safety and tolerability of fostamatinib (plus MTX) were consistent with previous studies. TRIAL REGISTRATION: OSKIRA-Asia-1 trial registration: https://clinicaltrials.gov, NCT01569074; OSKIRA-Asia-1X trial registration: https://clinicaltrials.gov, NCT01640054.
引用
- Tanaka Y, Millson D, Iwata S, et al. Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. Rheumatology (Oxford). 2021. PMID: 33254235. doi:10.1093/rheumatology/keaa732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。